Genetic Technologies Limited (ASX:GTG – Get Rating) insider Jerzy (George) Muchnicki sold 38,400,000 shares of the stock in a transaction that occurred on Monday, January 30th. The stock was sold at an average price of A$0.00 ($0.00), for a total transaction of A$38,400.00 ($27,042.25).
Genetic Technologies Stock Performance
The company has a debt-to-equity ratio of 3.97, a quick ratio of 3.72 and a current ratio of 3.86.
Get
Genetic Technologies alerts:
About Genetic Technologies
(Get Rating)
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate.
See Also
- 2023 Consumer Lending Study – Trends, Statistics, and Forecast
- Here's the Silver Lining with Snap Stock Earnings Collapse
- Mullen Automotive Stock, The Tide Has Turned
- Is BigBear.ai Stock a Diamond in the Rough?
- Apple: What's The Post-Earnings Play?
Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
Genetic Technologies Limited (ASX:GTG – Get Rating) insider Jerzy (George) Muchnicki sold 38,400,000 shares of the stock in a transaction that occurred on Monday, January 30th. The stock was sold at an average price of A$0.00 ($0.00), for a total transaction of A$38,400.00 ($27,042.25).
遺傳科技有限公司 (ASX: GTG — 獲得評級) 內幕傑茲 (喬治) 穆奇尼基出售 38,400,000 股票在週一發生的交易, 1 月 30 日.該股票的交易總額為 38,40 澳元（27,042.25 美元）的平均價格為 100 澳元（美元 0.00 美元）出售。
Genetic Technologies Stock Performance
The company has a debt-to-equity ratio of 3.97, a quick ratio of 3.72 and a current ratio of 3.86.
該公司的債務與權益比率為 3.97，快速比率為 3.72，流動比率為 3.86。
Get
Genetic Technologies
alerts:
About Genetic Technologies
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate.
基因科技有限公司是一家分子診斷公司，提供預測性基因檢測和風險評估工具，幫助醫生在美國、加拿大、歐洲、中東、非洲、拉丁美洲和亞太地區管理人們的健康。它在兩個部分工作, 易 DNA 和基因組/企業.
See Also
- 2023 Consumer Lending Study – Trends, Statistics, and Forecast
- Here's the Silver Lining with Snap Stock Earnings Collapse
- Mullen Automotive Stock, The Tide Has Turned
- Is BigBear.ai Stock a Diamond in the Rough?
- Apple: What's The Post-Earnings Play?
- 2023 消費者貸款研究-趨勢，統計數據和預測
- 這是帶有快速股票收益崩潰的銀色襯裡
- 馬倫汽車股票，潮汐已經轉向
- BigBear.ai 庫存是原石中的鑽石嗎？
- 蘋果：什麼是盈利後播放？
Receive News & Ratings for Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收有關遺傳技術的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收遺傳技術和相關公司的最新新聞和分析師評級的簡要每日摘要。
